Icagen Completes Phase I Study of Asthma Drug
Posted on: Thursday, 10 July 2008, 09:00 CDT
Icagen has successfully completed the Phase I multiple ascending dose clinical trial of senicapoc, a novel orally available small molecule inhibitor of the KCa3.1 potassium ion channel, which is being developed for the treatment of asthma.
The study results showed that senicapoc was well tolerated at all doses tested and in preliminary analyses exhibited predictable and dose proportional pharmacokinetics consistent with once-daily dosing. Additionally, there were no dose-limiting toxicities in any subject.
The company expects to initiate a Phase II proof-of-concept clinical trial in asthma during the second half of 2008. The initial Phase II proof-of-concept study is expected to be conducted in patients with allergen induced asthma.
The company expects to enroll approximately subjects in a short-duration study to examine the effect of senicapoc upon certain pulmonary function parameters following exposure of asthmatic patients to a known antigen. The study will be conducted at selected sites in the UK.
Source: Datamonitor
Related Articles
- Othera Initiates Dosing in Phase I/II Ocular Hypertension and Glaucoma Study
- Transition Therapeutics Initiates Dosing in Phase II Diabetes Study
- Peregrine Initiates Dosing in Phase II Lung Cancer Trial
- MediciNova Initiates Dosing in Phase II Asthma Trial
- Palatin Initiates Dosing in Phase IIa Hypertension Study
- KaloBios Completes Dosing in Phase I Study for Inflammatory Diseases
- Anadys Initiates Dosing in Phase I Cancer Trial
- Topigen Initiates Dosing in Phase II Asthma Trial
- Pharmasset Commences Dosing in Phase 3 Registration Studies of Clevudine for HBV
- Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
 |
 |
User Comments (0)
RSS Feeds